{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:06:47Z","timestamp":1789654007571,"version":"4.0.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["110579\/Z\/15\/Z"],"award-info":[{"award-number":["110579\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["110579\/Z\/15\/Z"],"award-info":[{"award-number":["110579\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["110579\/Z\/15\/Z"],"award-info":[{"award-number":["110579\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["110579\/Z\/15\/Z"],"award-info":[{"award-number":["110579\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["110579\/Z\/15\/Z"],"award-info":[{"award-number":["110579\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["110579\/Z\/15\/Z"],"award-info":[{"award-number":["110579\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["110579\/Z\/15\/Z"],"award-info":[{"award-number":["110579\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["110579\/Z\/15\/Z"],"award-info":[{"award-number":["110579\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["110579\/Z\/15\/Z"],"award-info":[{"award-number":["110579\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["110579\/Z\/15\/Z"],"award-info":[{"award-number":["110579\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MRC DTP PhD Studentship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In pursuit of a gene transfer agent with efficient pulmonary transduction, the UK Respiratory Gene Therapy Consortium has developed a lentiviral vector pseudotyped with the envelope proteins, F and HN from Sendai virus (rSIV.F\/HN). In contrast to other viral vectors, pulmonary rSIV.F\/HN delivery achieves sustained gene expression (\u2009~\u20092 years in mice) in the lungs and systemic circulation following a single dose. Here, we investigate the application of the rSIV.F\/HN vector-platform for wider indications, including systemic disorders that require serum expression of therapeutic proteins. To assess the potential for rSIV.F\/HN to produce systemic proteins, intravenous vector delivery was characterised and compared against intrapulmonary administration, achieved via \u2018nasal sniffing\u2019. Both delivery routes achieved sustained (at least 1 year) systemic expression of the secreted reporter protein Gaussia luciferase. Systemic rSIV.F\/HN delivery resulted in widespread protein expression across multiple organs, accompanied by the generation of significant anti-vector neutralising antibodies limiting vector readministration. Conversely, localised airway transduction was observed following pulmonary administration, which we have previously shown is not an impediment to efficient vector readministration. These data support intrapulmonary rSIV.F\/HN delivery for systemic protein production, with sustained high-level transgene expression and feasible readministration.<\/jats:p>","DOI":"10.1038\/s41434-026-00623-3","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:40:53Z","timestamp":1781793653000},"page":"586-595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of F\/HN-pseudotyped lentiviral vector following intravenous delivery to mice"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1060-0897","authenticated-orcid":false,"given":"Robyn V.","family":"Bell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil B.","family":"Faulkner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Sinadinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuixiang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana A.","family":"Viegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah R.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric WFW","family":"Alton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8254-4540","authenticated-orcid":false,"given":"Uta","family":"Griesenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"623_CR1","doi-asserted-by":"publisher","first-page":"12818","DOI":"10.1128\/JVI.79.20.12818-12827.2005","volume":"79","author":"PL Sinn","year":"2005","unstructured":"Sinn PL, Burnight ER, Hickey MA, Blissard GW, McCray PB. Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer. J Virol. 2005;79:12818\u201327.","journal-title":"J Virol"},{"key":"623_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/85664","volume":"19","author":"GP Kobinger","year":"2001","unstructured":"Kobinger GP, Weiner DJ, Yu QC, Wilson JM. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol. 2001;19:225\u201330.","journal-title":"Nat Biotechnol"},{"key":"623_CR3","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1128\/JVI.77.4.2607-2614.2003","volume":"77","author":"M Kobayashi","year":"2003","unstructured":"Kobayashi M, Iida A, Ueda Y, Hasegawa M. Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus. J Virol. 2003;77:2607\u201314.","journal-title":"J Virol"},{"key":"623_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/jgm.2695","volume":"15","author":"M Patel","year":"2013","unstructured":"Patel M, Giddings AM, Sechelski J, Olsen JC. High efficiency gene transfer to airways of mice using influenza hemagglutinin pseudotyped lentiviral vectors. J Gene Med. 2013;15:51\u201362.","journal-title":"J Gene Med"},{"key":"623_CR5","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/mt.2010.13","volume":"18","author":"K Mitomo","year":"2010","unstructured":"Mitomo K, Griesenbach U, Inoue M, Somerton L, Meng C, Akiba E, et al. Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes. Mol Ther. 2010;18:1173\u201382.","journal-title":"Mol Ther"},{"key":"623_CR6","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1164\/rccm.201206-1056OC","volume":"186","author":"U Griesenbach","year":"2012","unstructured":"Griesenbach U, Inoue M, Meng C, Farley R, Chan M, Newman NK, et al. Assessment of F\/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy. Am J Respir Crit Care Med. 2012;186:846\u201356.","journal-title":"Am J Respir Crit Care Med"},{"key":"623_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/thoraxjnl-2016-208406","volume":"72","author":"EWFW Alton","year":"2017","unstructured":"Alton EWFW, Beekman JM, Boyd AC, Brand J, Carlon MS, Connolly MM, et al. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. Thorax. 2017;72:137\u201347.","journal-title":"Thorax"},{"key":"623_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41434-018-0025-8","volume":"25","author":"MC Paul-Smith","year":"2018","unstructured":"Paul-Smith MC, Pytel KM, Gelinas JF, McIntosh J, Pringle I, Davies L, et al. The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins. Gene Ther. 2018;25:345\u201358.","journal-title":"Gene Ther"},{"key":"623_CR9","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1136\/thoraxjnl-2020-214656","volume":"75","author":"TK Tan","year":"2020","unstructured":"Tan TK, Gamlen TPE, Rijal P, Townsend AR, Gill DR, Hyde SC. Lung-targeting lentiviral vector for passive immunisation against influenza. Thorax. 2020;75:1112\u20135.","journal-title":"Thorax"},{"key":"623_CR10","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1136\/thoraxjnl-2021-217650","volume":"77","author":"Y Du","year":"2022","unstructured":"Du Y, Miah KM, Habib O, Meyer-Berg H, Conway CC, Viegas MA, et al. Lung directed antibody gene transfer confers protection against SARS-CoV-2 infection. Thorax. 2022;77:1229\u201336.","journal-title":"Thorax"},{"key":"623_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1006\/mthe.2002.0524","volume":"5","author":"U Griesenbach","year":"2002","unstructured":"Griesenbach U, Cassady RL, Ferrari S, Fukumura M, M\u00fcller C, Schmitt E, et al. The nasal epithelium as a factory for systemic protein delivery. Mol Ther. 2002;5:98\u2013103.","journal-title":"Mol Ther"},{"key":"623_CR12","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1097\/HS9.0000000000000540","volume":"5","author":"P Batty","year":"2021","unstructured":"Batty P, Lillicrap D. Hemophilia gene therapy: approaching the first licensed product. HemaSphere. 2021;5:e540.","journal-title":"HemaSphere"},{"key":"623_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1182\/blood-2018-99-118334","volume":"132","author":"AC Nathwani","year":"2018","unstructured":"Nathwani AC, Reiss U, Tuddenham E, Chowdary P, McIntosh J, Riddell A, et al. Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing \u201cempty viral particles\u201d on safety and efficacy of gene transfer. Blood. 2018;132:491.","journal-title":"Blood"},{"key":"623_CR14","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","volume":"28","author":"LA George","year":"2020","unstructured":"George LA, Ragni MV, Rasko JEJ, Raffini LJ, Samelson-Jones BJ, Ozelo M, et al. Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B. Mol Ther. 2020;28:2073\u201382.","journal-title":"Mol Ther"},{"key":"623_CR15","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","volume":"7","author":"A von Drygalski","year":"2023","unstructured":"von Drygalski A, Gomez E, Giermasz A, Castaman G, Key NS, Lattimore SU, et al. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy. Blood Adv. 2023;7:5671\u20139.","journal-title":"Blood Adv"},{"key":"623_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022;13:975803.","journal-title":"Front Immunol"},{"key":"623_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"C Schneider","year":"2012","unstructured":"Schneider C, Rasband W, Eliceiri K. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"623_CR18","doi-asserted-by":"crossref","unstructured":"Cantore A, Ranzani M, Bartholomae CC, Volpin M, Valle PD, Sanvito F et al. Liver-directed lentiviral gene therapy in a dog model of hemophilia B. Sci Transl Med. 2015:7;277.","DOI":"10.1126\/scitranslmed.aaa1405"},{"key":"623_CR19","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1182\/blood-2012-05-432591","volume":"120","author":"A Cantore","year":"2012","unstructured":"Cantore A, Nair N, Valle PD, Matteo M, M\u00e0trai J, Sanvito F, et al. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood. 2012;120:4517\u201320.","journal-title":"Blood"},{"key":"623_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32576-7","volume":"13","author":"CT Nicolas","year":"2022","unstructured":"Nicolas CT, VanLith CJ, Hickey RD, Du Z, Hillin LG, Guthman RM, et al. In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions. Nat Commun. 2022;13:5012.","journal-title":"Nat Commun"},{"key":"623_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.omtm.2022.07.002","volume":"26","author":"RJ Munday","year":"2022","unstructured":"Munday RJ, Coradin T, Nimmo R, Lad Y, Hyde SC, Mitrophanos K, et al. Sendai F\/HN pseudotyped lentiviral vector transduces human ciliated and non-ciliated airway cells using \u03b1 2,3 sialylated receptors. Mol Ther Methods Clin Dev. 2022;26:239\u201352.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"623_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF01314130","volume":"75","author":"Y Ito","year":"1983","unstructured":"Ito Y, Yamamoto F, Takano M, Maeno K, Shimokata K, Iinuma M, et al. Detection of cellular receptors for Sendai virus in mouse tissue sections. Arch Virol. 1983;75:103\u201313.","journal-title":"Arch Virol"},{"key":"623_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/79463","volume":"18","author":"Y Yonemitsu","year":"2000","unstructured":"Yonemitsu Y, Kitson C, Ferrari S, Farley R, Griesenbach U, Judd D, et al. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol. 2000;18:1\u20134.","journal-title":"Nat Biotechnol"},{"key":"623_CR24","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1096\/fj.00-0460fje","volume":"15","author":"I Masaki","year":"2001","unstructured":"Masaki I, Yonemitsu Y, Komori K, Ueno H, Nakashima Y, Nakagawa K, et al. Recombinant Sendai virus-mediated gene transfer to vasculature: a new class of efficient gene transfer vector to the vascular system. FASEB J. 2001;15:1294\u20136.","journal-title":"FASEB J"},{"key":"623_CR25","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/sj.gt.3301486","volume":"8","author":"A Shiotani","year":"2001","unstructured":"Shiotani A, Fukumura M, Maeda M, Hou X, Inoue M, Kanamori T, et al. Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector. Gene Ther. 2001;8:1043\u201350.","journal-title":"Gene Ther"},{"key":"623_CR26","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1046\/j.0953-816x.2001.01606.x","volume":"13","author":"S Suzuki","year":"2001","unstructured":"Suzuki S, Li AJ, Ishisaki A, Hou X, Hasegawa M, Fukumura M, et al. Feeding suppression by fibroblast growth factor-1 is accompanied by selective induction of heat shock protein 27 in hypothalamic astrocytes. Eur J Neurosci. 2001;13:2299\u2013308.","journal-title":"Eur J Neurosci"},{"key":"623_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1006\/exer.2002.1177","volume":"75","author":"Y Ikeda","year":"2002","unstructured":"Ikeda Y, Yonemitsu Y, Sakamoto T, Ishibashi T, Ueno H, Kato A, et al. Recombinant Sendai virus-mediated gene transfer into adult rat retinal tissue: efficient gene transfer by brief exposure. Exp Eye Res. 2002;75:39\u201348.","journal-title":"Exp Eye Res"},{"key":"623_CR28","doi-asserted-by":"crossref","unstructured":"Miyamoto K, Akiyama M, Tamura F, Isomi M, Yamakawa H, Sadahiro T, et al. Direct In Vivo Reprogramming with Sendai Virus Vectors Improves Cardiac Function after Myocardial Infarction. Cell Stem Cell. 2018;22:91\u2013103.e5","DOI":"10.1016\/j.stem.2017.11.010"},{"key":"623_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7325","volume":"11","author":"M Milani","year":"2019","unstructured":"Milani M, Annoni A, Moalli F, Liu T, Cesana D, Calabria A, et al. Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates. Sci Transl Med. 2019;11:eaav7325.","journal-title":"Sci Transl Med"},{"key":"623_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","volume":"28","author":"JL Shirley","year":"2020","unstructured":"Shirley JL, de, Jong YP, Terhorst C, Herzog RW. Immune Responses to Viral Gene Therapy Vectors. Mol Ther. 2020;28:709\u201322.","journal-title":"Mol Ther"},{"key":"623_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.stemcr.2020.02.001","volume":"14","author":"T Shinohara","year":"2020","unstructured":"Shinohara T, Kanatsu-Shinohara M. Transgenesis and genome editing of mouse spermatogonial stem cells by lentivirus pseudotyped with Sendai virus F protein. Stem Cell Rep. 2020;14:447\u201361.","journal-title":"Stem Cell Rep"},{"key":"623_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.omtm.2019.11.004","volume":"16","author":"DA Carbonaro-Sarracino","year":"2020","unstructured":"Carbonaro-Sarracino DA, Tarantal AF, Lee CCI, Kaufman ML, Wandro S, Jin X, et al. Re-administration of lentiviral vector for in vivo gene therapy in rhesus monkeys and ADA-deficient mice. Mol Ther Methods Clin Dev. 2020;16:78\u201393.","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00623-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00623-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00623-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:58:37Z","timestamp":1789653517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00623-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["623"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00623-3","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EWFWA is a Consultant and Advisory Board member, Boehringer Ingelheim. Founder Director and Consultant, AlveoGene Ltd. UG is a co-founder and consultant for AlveoGene Ltd, a consultant for Boehringer Ingelheim and a non-Executive Director of the Cell and Gene Therapy Catapult. The authors have a patent application related to this work.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal procedures were performed in accordance with the UK Home Office Project and Personal licence regulations under the Animal Scientific Procedure Act (1986) and approved by the Imperial College Animal Welfare Ethics Review Body (AWERB).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}